239 related articles for article (PubMed ID: 22173427)
1. Bleeding with dabigatran (Pradaxa).
Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98. PubMed ID: 22173427
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
Ahmad Y; Lip GY
Heart; 2012 Oct; 98(19):1404-6. PubMed ID: 22698856
[No Abstract] [Full Text] [Related]
4. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran in clinical practice.
Nagarakanti R; Ellis CR
Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology and therapeutic use of dabigatran etexilate.
Sarah S
J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Bendel SD; Bona R; Baker WL
Adv Ther; 2011 Jun; 28(6):460-72. PubMed ID: 21533567
[TBL] [Abstract][Full Text] [Related]
10. The use of dabigatran in elderly patients.
Legrand M; Mateo J; Aribaud A; Ginisty S; Eftekhari P; Huy PT; Drouet L; Payen D
Arch Intern Med; 2011 Jul; 171(14):1285-6. PubMed ID: 21788545
[TBL] [Abstract][Full Text] [Related]
11. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Davis C; Robertson C; Shivakumar S; Lee M
J Can Dent Assoc; 2013; 79():d74. PubMed ID: 23920075
[TBL] [Abstract][Full Text] [Related]
12. Should dabigatran replace warfarin for stroke prevention in AF?
Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
Iyer V; Singh HS; Reiffel JA
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):237-47. PubMed ID: 22388002
[TBL] [Abstract][Full Text] [Related]
14. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
[TBL] [Abstract][Full Text] [Related]
16. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Avecilla ST; Ferrell C; Chandler WL; Reyes M
Am J Clin Pathol; 2012 Apr; 137(4):572-4. PubMed ID: 22431533
[TBL] [Abstract][Full Text] [Related]
17. [Dabigatran: a new therapeutic alternative in the prevention of stroke].
Gállego J; Gil Alzueta MC
Neurologia; 2012 Mar; 27 Suppl 1():39-45. PubMed ID: 22682209
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
19. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Langkilde LK; Bergholdt Asmussen M; Overgaard M
J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
